Pfizer has ceased development of its oral GLP-1 weight loss drug candidate, danuglipron, after a study participant ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of ...

Pfizer offers a substantial 6.7% dividend yield and has increased its dividend for 16 consecutive years. The stock trades at a forward P/E of just 8.7, close to historical lows. Despite policy ...

Pfizer (PFE) is ending a late-stage trial of its once-daily GLP-1 pill, Danuglipron, after a participant experienced a liver ...

In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of ...

Pfizer and Allergan have confirmed that they ... driven by the potential savings they are able to deliver to healthcare systems. The ISPE Singapore Affiliate Conference & Exhibition is one of ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

Is now the time to buy Supernus Pharmaceuticals? Access our full analysis of the earnings results here, it’s free. Originally spun off from Pfizer in 2013 as the world's largest pure-play animal ...

Pfizer shares moved lower in premarket trading Monday after the drugmaker said it is scrapping its experimental weight-loss pill danuglipron, keeping the company on the sidelines of the booming ...

A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White ...

Myriad reasons underlie the negative sentiment toward the healthcare sector, but in some instances, this dour take isn't entirely warranted. Pharmaceutical titan Pfizer (NYSE: PFE) is a case in point.